{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:08Z","timestamp":1789532948444,"version":"build-2803163510"},"reference-count":26,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P\u00a0&amp;lt; .05) and less refractoriness (4.5% vs 14.1%; P\u00a0&amp;lt; .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P\u00a0&amp;lt; .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P\u00a0&amp;lt; .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008028","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T18:57:01Z","timestamp":1659725821000},"page":"6219-6227","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["Real-world effectiveness of caplacizumab vs the standard of care in\u00a0immune thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-4886","authenticated-orcid":false,"given":"Cristina Pascual","family":"Izquierdo","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n (HGUGM) Madrid, Instituto de Investigaci\u00f3n Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-855X","authenticated-orcid":false,"given":"Mar\u00eda Eva","family":"Mingot-Castellano","sequence":"additional","affiliation":[{"name":"2Hematology, Hospital Universitario Virgen del Roc\u00edo, Instituto de Biomedicina de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana E. Kerguelen","family":"Fuentes","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Hemotherapy, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Garc\u00eda-Arroba Peinado","sequence":"additional","affiliation":[{"name":"4Banc de Sang i Teixits, Hospital Universitario Joan XXIII, Tarragona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-4508","authenticated-orcid":false,"given":"Joan","family":"Cid","sequence":"additional","affiliation":[{"name":"5Apheresis and Cellular Therapy Unit, Department of Hemotherapy & Hemostasis, ICMHO, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Moraima","family":"Jimenez","sequence":"additional","affiliation":[{"name":"6Department of Hematology, University Hospital Vall d\u2019Hebron, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valcarcel","sequence":"additional","affiliation":[{"name":"6Department of Hematology, University Hospital Vall d\u2019Hebron, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"G\u00f3mez-Segu\u00ed","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Martin","sequence":"additional","affiliation":[{"name":"8Therapeutic Apheresis Unit, Hematology Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Goterris","sequence":"additional","affiliation":[{"name":"9Hematology Service, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"10Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Tall\u00f3n","sequence":"additional","affiliation":[{"name":"11Hospital Virgen Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Varea","sequence":"additional","affiliation":[{"name":"12Hospital San Chinarro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"13Hospital Universitario de A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Garc\u00eda-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"14Hospital de Bellvitge, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00edriam","family":"Vara","sequence":"additional","affiliation":[{"name":"15Hematology Department, Hospital Universitario de Cruces, Baracaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Fern\u00e1ndez","family":"Zarzoso","sequence":"additional","affiliation":[{"name":"16Hospital Universitario Dr. Peset, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-6004","authenticated-orcid":false,"given":"Faustino","family":"Garc\u00eda-Candel","sequence":"additional","affiliation":[{"name":"17Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Liz","family":"Paciello","sequence":"additional","affiliation":[{"name":"18Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-6754","authenticated-orcid":false,"given":"Irene","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"18Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saioa","family":"Zalba","sequence":"additional","affiliation":[{"name":"19Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-7055","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Campuzano","sequence":"additional","affiliation":[{"name":"20Hospital Universitario Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5992-1961","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Gala","sequence":"additional","affiliation":[{"name":"21Hospital Universitario Central de Asturias, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Vid\u00e1n","family":"Est\u00e9vez","sequence":"additional","affiliation":[{"name":"22Apheresis & Transfusion Unit, Department of Hematology & Hemotherapy, CAULE, Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma Moreno","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Hospital Universitario Ramon y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez Lorenzo","sequence":"additional","affiliation":[{"name":"24Department of Hematology Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Hematologia Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Gonz\u00e1lez","family":"Arias","sequence":"additional","affiliation":[{"name":"25Hospital Universitario de Villalba, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Freir\u00eda","sequence":"additional","affiliation":[{"name":"26Hospital Universitario de Castellon, Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sol\u00e9","sequence":"additional","affiliation":[{"name":"27Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Francisca","family":"\u00c1vila Idrovo","sequence":"additional","affiliation":[{"name":"28Hospital Universitario de Canarias, Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Hern\u00e1ndez Castellet","sequence":"additional","affiliation":[{"name":"29Hospital Puerta del Mar, C\u00e1diz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naylen","family":"Cruz","sequence":"additional","affiliation":[{"name":"30Hospital Universitario Dr. Negr\u00edn, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0678","authenticated-orcid":false,"given":"Esperanza","family":"Lavilla","sequence":"additional","affiliation":[{"name":"31Hospital Universitario Lucus Augusti, Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"P\u00e9rez-Monta\u00f1a","sequence":"additional","affiliation":[{"name":"32Hospital Universitario Son Espases, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Ander","family":"Atucha","sequence":"additional","affiliation":[{"name":"33Hospital de Basurto, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Esperanza","family":"Moreno Beltr\u00e1n","sequence":"additional","affiliation":[{"name":"34Hospital Costa del Sol, Marbella, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju\u00e1n Ram\u00f3n","family":"Moreno Mac\u00edas","sequence":"additional","affiliation":[{"name":"35Hospital Universitario de Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Salinas","sequence":"additional","affiliation":[{"name":"36Hospital del Sagrat Cor, Universitat Internacional de Catalunya; Banc de Sang i Teixits de Catalunya, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"del Rio-Garma","sequence":"additional","affiliation":[{"name":"37Department of Hematology, University Hospital of Ourense, Ourense, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"7","key":"2023053018351189900_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023053018351189900_bib2","first-page":"1","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"10","key":"2023053018351189900_bib3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2023053018351189900_bib4","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023053018351189900_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jca.21894","article-title":"Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: a nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura","volume":"36","author":"Pascual-Izquierdo","year":"2021","journal-title":"J\u00a0Clin Apher"},{"issue":"1","key":"2023053018351189900_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13023-019-1240-0","article-title":"Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study","volume":"14","author":"Miesbach","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2023053018351189900_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0039-1679907","article-title":"Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP Registry","volume":"119","author":"Mancini","year":"2019","journal-title":"Thromb Haemost"},{"issue":"1","key":"2023053018351189900_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00277-021-04685-8","article-title":"Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era","volume":"101","author":"del R\u00edo-Garma","year":"2022","journal-title":"Ann Hematol"},{"issue":"10","key":"2023053018351189900_bib9","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2023053018351189900_bib10","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","article-title":"Nine-i Investigators. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura","volume":"45","author":"Azoulay","year":"2019","journal-title":"Intensive Care Med"},{"issue":"6","key":"2023053018351189900_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023053018351189900_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023053018351189900_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"Knoebl","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023053018351189900_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2023053018351189900_bib15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2023053018351189900_bib16","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2023053018351189900_bib17","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2023053018351189900_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023053018351189900_bib19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery","volume":"2018","author":"George","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"21","key":"2023053018351189900_bib20","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s Disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023053018351189900_bib21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023053018351189900_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.2020009654","article-title":"TTP: the evolution of clinical practice","volume":"137","author":"George","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023053018351189900_bib23","doi-asserted-by":"crossref","first-page":"103011","DOI":"10.1016\/j.transci.2020.103011","article-title":"Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, Steroids, Plasma Exchange, Rituximab, and Intravenous Immunoglobulins (CASPERI)","volume":"60","author":"Cid","year":"2021","journal-title":"Transfus Apheresis Sci"},{"issue":"13","key":"2023053018351189900_bib24","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2023053018351189900_bib25","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023053018351189900_bib26","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/ajh.25715","article-title":"Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab","volume":"95","author":"Sukumar","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6219\/2054414\/blooda_adv-2022-008028-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6219\/2054414\/blooda_adv-2022-008028-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:37:31Z","timestamp":1685471851000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/24\/6219\/486123\/Real-world-effectiveness-of-caplacizumab-vs-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008028","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}